Tumor DNA (Deoxyribose Nucleic Acid) vaccine and virus vector vaccine taking mucoprotein 1 and surviving as targets

A DNA vaccine and anti-tumor immunity technology, applied in the field of tumor DNA vaccines and virus vector vaccines, can solve the problems of weak immunogenicity of DNA vector vaccines, relatively large safety hazards and difficult preparation of recombinant poxvirus vaccines in primary vaccination

Inactive Publication Date: 2014-09-03
CHANGCHUN BCHT BIOTECH
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

From the discovery of MUC1 to the present, a lot of vaccine research work has been carried out with it, and some vaccines have entered the stage of human clinical research, but most of them are traditional polypeptide, protein or dendritic cell (DC) vaccines, Most of these vaccines have problems such as poor immunogenicity or difficulty in preparation; the genetic vaccines that have entered the clinic are mainly recombinant poxvirus vaccines. Although no toxicity has been detected, there are still relatively large safety hazards in primary vaccination-boosting of recombinant poxvirus vaccines directly. , and the clinical effect is not very satisfactory; DNA carrier vaccine is still basically in the preclinical rese

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor DNA (Deoxyribose Nucleic Acid) vaccine and virus vector vaccine taking mucoprotein 1 and surviving as targets
  • Tumor DNA (Deoxyribose Nucleic Acid) vaccine and virus vector vaccine taking mucoprotein 1 and surviving as targets
  • Tumor DNA (Deoxyribose Nucleic Acid) vaccine and virus vector vaccine taking mucoprotein 1 and surviving as targets

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0033] 1. The preparation method and conditions of the above-mentioned fragment 33M and S8

[0034] Preparation of 1.33M

[0035] MUC1VNTR is a repeat fragment containing 60 bases, GenBank number is NM_002456 (SEQ ID NO: 1). Two pairs of primers were designed according to the base sequence of a VNTR, and a VNTR (1m) repeat region fragment was synthesized by overlapping extension PCR (SOE PCR), and then digested with restriction endonucleases SalI and XhoI to produce the same sticky end characteristics, sequentially connected to construct 33M gene fragments. The specific method is as follows:

[0036] 1) Overlap extension PCR technology

[0037] The PCR reaction conditions are: 95°C for 20s, 55°C for 20s, 72°C for 30s, 30 cycles, using primers P1 (SEQ ID NO:2) and P2 (SEQ ID NO:3) to amplify one copy of MUC1VNTR without ATG (abbreviated as m), using P2 and P3 (SEQ ID NO: 4) as primers to amplify one copy of ATG-containing MUC1VNTR (abbreviated as Am) fragment.

[0038] 2) ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of tumor DNA (Deoxyribose Nucleic Acid) vaccines and virus vector vaccines, and in particular relates to recombinant DNA vectors VR-S8 and VR-MS, recombinant adenoviruses AD-S8 and Ad-MS and a recombinant poxvirus MVA-MS vaccine, as well as application of DNA vaccines and optimized combination of immunization ways between virus vector vaccines to preparation of antitumor vaccines.

Description

[0001] This application is a divisional application, the original application date is December 4, 2009, the application number is 200910252427.X, and the name is "tumor DNA vaccine and virus vector vaccine targeting mucin 1 and survivin" . technical field [0002] The invention relates to the field of tumor DNA vaccine and virus vector vaccine. Specifically, the present invention relates to recombinant DNA vector VR-S8 and VR-MS, recombinant adenovirus Ad-S8 and Ad-MS and recombinant poxvirus MVA-MS vaccine, and DNA vaccine and viral vector vaccine and viral vector vaccine The application of the optimized combination of immunization methods in the preparation of anti-tumor vaccines. Background technique [0003] Survivin is a member of the inhibitor of apoptosis protein (IAP) family, has dual functions of anti-apoptosis and regulation of cell division, and is widely expressed in various embryonic tissues and cancer cells, but not in normal terminally differentiated cells ....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61K39/00A61P35/00
Inventor 孔维张海红于湘晖于永慧
Owner CHANGCHUN BCHT BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap